USRE42718EExpiredUtility
Crude extracts from andrographis paniculata
Assignee: HUTCHISON MEDIPHARMA ENTPR LTDPriority: Apr 28, 2004Filed: Mar 4, 2010Granted: Sep 20, 2011
Est. expiryApr 28, 2024(expired)· nominal 20-yr term from priority
A61P 37/04A61P 9/04A61P 3/10A61P 37/06A61P 37/02A61P 35/02A61P 29/00A61P 27/02A61P 31/04A61P 31/18A61P 25/28A61P 1/04A61P 11/06A61P 1/02A61P 21/00A61P 1/18A61P 17/00A61P 17/06A61P 1/00A61K 36/19A61K 31/365
80
PatentIndex Score
4
Cited by
152
References
13
Claims
Abstract
This invention relates to a method of inhibiting TNFα or IL-1β expression with an extract of Andrographis paniculata. The extract contains andrographolide, 14-deoxy-andrographolide, 14-deoxy-11,12-dehydrogen-andrographolide, and neoandrographolide.
Claims
exact text as granted — not AI-modified1. A method of treating an inflammatory bowel disease in a subject in recognized need thereof, comprising administering to the subject an effective amount of an extract of Andrographispaniculata, wherein the extract contains 2-20% by weight andrographolide, 1-6% by weight 14-deoxy-andrographolide, 1-12 1.0-7% by weight 14-deoxy-11,12-dehydrogen-andrographolide, and 1-5% by weight neoandrographolide.
2. The method of claim 1 , wherein the extract contains 3-8% by weight andrographolide, 3 1-5% by weight 14-deoxy-andrographolide, 1.0-7-9% by weight 14-deoxy-11,12-dehydrogen-andrographolide, and 2-4% by weight neoandrographolide.
3. The method of claim 2 , wherein the extract contains 4.2% by weight andrographolide, 4.4% by weight 14-deoxy-andrograpliolide, 8% by weight 14-deoxy-11,12-dehydrogen-andrographolide, and 2.1% by weight neoandrographolide.
4. The method of claim 1 , wherein the inflammatory bowel disease is Crohn's disease.
5. The method of claim 1 , wherein the inflammatory bowel disease is ulcerative colitis.
6. The method of claim 5 , wherein the extract contains 3-8% by weight andrographolide, 3 1-5% by weight 14-deoxy-andrographolide, 1.0-7-9% by weight 14-deoxy-11,12-dehydrogen-andrographolide, and 2-4% by weight neoandrographolide.
7. The method of claim 6 , wherein the extract contains 4.2% by weight andrographolide, 4.4% by weight 14-deoxy-andrographolide, 8% by weight 14-deoxy-11,12-dehydrogen-andrographolide, and 2.1% by weight neoandrographolide.
8. A method of treating an inflammatory bowel disease comprising administering to a patient in recognized need of such treatment an effective amount for treating of an extract of Andrographis paniculata, comprising: 2-20% by weight andrographolide, 1.0-7% by weight 14-deoxy-11,12-dehydrogen-andrographolide, and 1-5% by weight neoandrographolide.
9. A method of treating an inflammatory bowel disease comprising administering to a patient in recognized need of such treatment an effective amount for treating of an extract of Andrographis paniculata, comprising 2-20% by weight andrographolide, 14-deoxy-andrographolide, 1.0-7% by weight 14-deoxy-11,12-dehydrogen-andrographolide, and 1-5% by weight neoandrographolide.
10. The method of claim 8 wherein said inflammatory bowel disease is Crohn's disease.
11. The method of claim 8 wherein said inflammatory bowel disease is ulcerative colitis.
12. The method of claim 9 wherein said inflammatory bowel disease is Crohn's disease.
13. The method of claim 9 wherein said inflammatory bowel disease is ulcerative colitis.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.